Back to results
US 2019/0240198 A1Published application
Formulations and methods for the treatment of cancers
OwnerDean G. Tang, Xin Cheninventors
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.
Claims37
A formulation, comprising:
- an androgen receptor signaling inhibitor;
- and
- a B-cell lymphoma 2 inhibitor,
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A formulation, comprising:
- an androgen receptor signaling inhibitor;
- a B-cell lymphoma 2 inhibitor,
- a Bromodomain and Extra-Terminal protein inhibitor;
- and,
- a phosphoinositide 3-kinase inhibitor.
2 more elements
Dependencies are inferred from the claim text.